Publication:
Effect of tamoxifen on ovarian reserve: a randomized controlled assessor-blind trial in a mouse model

dc.contributor.coauthorAkduman, Ayse Topcu
dc.contributor.coauthorOzerkan, Kemal
dc.contributor.coauthorZik, Berrin
dc.contributor.coauthorPeker, Sabire
dc.contributor.coauthorAvci, Berrin
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAta, Mustafa Barış
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:28:35Z
dc.date.issued2014
dc.description.abstractObjective: To determine whether tamoxifen (TMX) exposure causes a permanent decrease in ovarian reserve. Material and Methods: A randomized controlled assessor-blind trial including 30 adult female inbred BALB/C mice. Fifteen mice in the TMX group were given a single 0.1-mg dose of TMX intraperitoneally. Fifteen mice in the control group were given a single dose of the vehicle at the same volume intraperitoneally. Two cycles later, blood samples were collected for determination of anti-Mullerian hormone (AMH) levels, and the mice were sacrificed. After gonadectomy, ovarian size was measured, and follicles were counted under light microscopy. Results: Median serum AMH levels were 6.53 and 6.14 ng/ml in the control and TMX groups, respectively (p=0.03). Ovarian size was significantly decreased in the TMX group. While the number of primordial (9 vs 8), primary (6 vs 3), and secondary (4.5 vs 5) follicles were similar, there were significantly fewer preantral (11.5 vs 6, p<0.01) and antral (2 vs 1, p: 0.03) follicles, as well as corpora lutea (6 vs 3, p: 0.04), in the TMX group than in the control group. The number of atretic (2.5 vs 5, p: 0.048) follicles was increased in the TMX group. Conclusion: Tamoxifen administration leads to arrested growth of gonadotropin-sensitive follicles, while insensitive follicles can remain unaffected. TMX is merely an endocrine disruptor, and it does not cause a decrease in primordial follicle pool.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume15
dc.identifier.doi10.5152/jtgga.2014.14166
dc.identifier.eissn1309-0380
dc.identifier.issn1309-0399
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-84919777399
dc.identifier.urihttps://doi.org/10.5152/jtgga.2014.14166
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11914
dc.identifier.wos420676800006
dc.keywordsTamoxifen
dc.keywordsAnti-mullerian hormone
dc.keywordsOvarian reserve
dc.keywordsFolliculogenesis
dc.keywordsAntral follicle count
dc.keywordsFollicle-stimulating-hormone
dc.keywordsGranulosa-cell differentiation
dc.keywordsAromatase inhibitors
dc.keywordsBreast-cancer
dc.keywordsEstrogens
dc.keywordsToxicity
dc.keywordsGrowth
dc.language.isoeng
dc.publisherGalenos Yayınevi
dc.relation.ispartofJournal of The Turkish-German Gynecological Association
dc.subjectObstetrics and gynecology
dc.titleEffect of tamoxifen on ovarian reserve: a randomized controlled assessor-blind trial in a mouse model
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAta, Mustafa Barış
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files